Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909920 | 0.96 | ACHE (0.42) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL4910784 | 0.96 | HRH3 (0.39) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL4911755 | 0.93 | HRH3 (0.37) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL4915255 | 0.90 | DRD2 (0.40) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL4909403 | 0.90 | MAPK14 (0.36) | OXTRMAPK14 | |
| SCHEMBL4910877 | 0.90 | DRD2 (0.40) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL4933826 | 0.90 | MAPK14 (0.37) | DRD3DRD2OXTRMAPK14 | |
| SCHEMBL4933816 | 0.90 | MAPK14 (0.37) | DRD3DRD2OXTRMAPK14 | |
| SCHEMBL4914320 | 0.89 | ALDH1A1 (0.37) | DRD3HRH3ACHEHTR4DRD2 | |
| SCHEMBL14258848 | 0.89 | OXTR (0.36) | OXTRAVPR2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | DRD3 176/4885HRH3 734/4885ACHE 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.